Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.
News from Twitter
Looking forward to meeting you all at #BIO2017 San Diego, June 19-22, 2017. Let's schedule: 1 (800) 445-1839 // +41 22 518 2100
Scopis launches mixed reality spinal surgery navigator with Microsoft’s HoloLens captis.com/scopis-la…
One Drop, MannKind ink partnership for connected, inhaled diabetes tech captis.com/?p=33587
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News